19060-64-1

Basic information

• Product Name: N-(4-AMINO-PHENYL)-NICOTINAMIDE
• Synonyms: N-(4-AMINO-PHENYL)-NICOTINAMIDE;AKOS BBV-007649;UKRORGSYN-BB BBV-007649;N-(4-aminophenyl)nicotinamide(SALTDATA: FREE)
• CAS NO: 19060-64-1
• Molecular Formula: C₁₂H₁₁N₃O
• Molecular Weight: 213.24
• Mol File: 19060-64-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 329.4°C at 760 mmHg
• Flash Point: 153°C
• Appearance: /
• Density: 1.301g/cm³
• Vapor Pressure: 0.000178mmHg at 25°C
• Refractive Index: 1.697
• CAS DataBase Reference: N-(4-AMINO-PHENYL)-NICOTINAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-AMINO-PHENYL)-NICOTINAMIDE(19060-64-1)
• EPA Substance Registry System: N-(4-AMINO-PHENYL)-NICOTINAMIDE(19060-64-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 19060-64-1(Hazardous Substances Data)

Usage

General Description

N-(4-amino-phenyl)-nicotinamide, also known as 4APNA, is a chemical compound with the molecular formula C12H11N3O. It is a derivative of nicotinamide and contains an amino group attached to the 4-position of the phenyl ring. 4APNA is commonly used in research and pharmaceuticals due to its potential applications in the development of drugs and medical treatments. It is known to exhibit various biological activities, including antitumor and antimicrobial properties. Additionally, 4APNA has been studied for its potential use in the treatment of diabetes and other metabolic disorders. Overall, N-(4-amino-phenyl)-nicotinamide is a versatile chemical compound with diverse potential applications in the fields of medicine and biochemistry.

InChI:InChI=1/C12H11N3O/c13-10-3-5-11(6-4-10)15-12(16)9-2-1-7-14-8-9/h1-8H,13H2,(H,15,16)

Upstream product

• 10400-19-8 3-pyridinecarbonyl chloride 
• 59-67-6 nicotinic acid 
• 100-01-6 4-nitro-aniline 
• 13160-62-8 N-(4-nitrophenyl)-3-pyridinecarboxamide 
• 20260-53-1 pyridine-3-carbonyl chloride hydrochloride 

Relevant articles and documents

Catalytic hydrogenation of: N -4-nitrophenyl nicotinamide in a micro-packed bed reactor

Recent advancements in micro-flow technologies and a drive toward more efficient, greener and safer processes have led to a renaissance in flow-chemistry for pharmaceutical production. In this work, we demonstrate the use of a stabilized Pd nanoparticle-organic-silica catalyst to selectively catalyze the hydrogenation of N-4-nitrophenyl nicotinamide, a functionalized active pharmaceutical ingredient (API) surrogate. Extensive catalyst and reactor characterization is provided to establish an in-depth understanding of the unique multiphase dynamics within the micro-packed bed reactor, including the identification of a large liquid holdup (74-84%), rapid multiphase mass transfer (kma > 1 s-1), and liquid residence time distributions. A kinetic analysis has revealed that the surface catalyzed hydrogenation progresses through a condensation mechanism whereby an azo dimer intermediate is formed and rapidly consumed. Finally, a parametric study was performed at various pressures, temperatures, residence times and flow regimes to achieve quantitative chemoselective conversion of the nitroarene to the corresponding primary amine.

Synthesis and biological evaluation of 1-(2-aminophenyl)-3-arylurea derivatives as potential EphA2 and HDAC dual inhibitors

A series of 1-(2-aminophenyl)-3-arylurea novel derivatives were synthesized and evaluated against Ephrin type-A receptor 2 (EphA2) and histone deacetylases (HDACs) kinase. Most of the compounds exhibited inhibitory activity against EphA2 and HDAC. The antiproliferative activities were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (thiazolyl blue, tetrazolium blue) against the human cancer cell lines HCT116, K562 and MCF7. Compounds 5a and b showed the most potent inhibitory activity against EphA2 and HDAC. However, compound 5b exhibited higher potency against HCT116 (IC50=5.29 μM) and MCF7 (IC50=7.42 μM). 1-(2-Aminophenyl)-3-arylurea analogues may serve as new EphA2-HDAC dual inhibitors.